Piramal Pharma Share Price Gains Over 14% Post Q2 FY27 Earnings Results: Total Income Up 25.8% YoY

On October 27, 2026, Piramal Pharma Limited reported its consolidated unaudited financial results for the quarter and half year ended September 30, 2026, as per the exchange filings. 

Piramal Pharma Q2 FY27 Earnings Results 

Piramal Pharma Limited has reported a 25.8% year-on-year increase in total income for the quarter ending September 30, 2026, reaching ₹2,652.99 crore. This marks a rise from ₹2,109.32 crore in the same period last year and a 12.4% increase from ₹2,359.33 crore in the previous quarter ending June 2026. 

For the September 2026 quarter, the company recorded a net profit of ₹5.03 crore. This is a turnaround from a net loss of ₹99.22 crore in the corresponding quarter of the previous year and a net loss of ₹69.38 crore in the June 2026 quarter.  

Quarterly EBITDA increased 72% year-on-year to ₹385 crore 

Half-Yearly Financial Overview 

In the half-year period ending September 30, 2026, the company's total income increased by 22.2% year-on-year to ₹5,012.32 crore, up from ₹4,101.44 crore in the same period last year. The net loss for this period narrowed to ₹64.35 crore, compared to a net loss of ₹180.92 crore in the corresponding period of the previous year. 

Annual Financial Summary for FY26 

For the financial year ending March 31, 2026, Piramal Pharma Limited reported a total income of ₹9,082.38 crore. The net loss for FY26 stood at ₹325.94 crore. These figures provide a comprehensive view of the company's financial performance over the fiscal year. 

Read More: Acutaas Chemicals Share Price Surges Over 14% After Q2FY27 Net Profit Rises 71.4%! 

Segment Operations Breakdown 

The Contract Development and Manufacturing Organization business led the performance, generating quarterly revenue of ₹1,424 crore. The segment witnessed strong RFP activity and added 22 new customers. 

Complex Hospital Generics recorded a revenue of ₹849 crore, while Consumer Healthcare registered ₹359 crore. Inhalation anesthesia sales in ex-US markets heavily supported this segment growth. 

Balance Sheet Analysis 

The total equity of the firm stood at ₹8,165 crore as of September 30, 2026. Net debt for the period was recorded at ₹4,859 crore. 

Total assets reached ₹13,023 crore, with net fixed assets accounting for ₹10,448 crore. Net working capital was reported at ₹2,260 crore. 

Strategic Growth Outlook 

Chairperson Nandini Piramal highlighted that the strong performance was driven by healthy demand and operating leverage. The company successfully completed 12 regulatory inspections during the half-year. 

Management upgraded its full-year revenue growth outlook to a range of 19% to 20%. The company expects meaningfully higher profitability during the second half of the fiscal year. 

Piramal Pharma Share Price Performance 

As of October 28, 2026, at 11:39 AM, Piramal Pharma share price on NSE was trading at ₹227.42 up by 14.44% from the previous closing price. 

Conclusion 

Piramal Pharma Limited's total income for the September 2026 quarter rose by 25.8% YoY to ₹2,652.99 crore. The company achieved a net profit of ₹5.03 crore, reversing the previous year's loss of ₹99.22 crore. For the half-year ending September 30, 2026, total income increased by 22.2% YoY to ₹5,012.32 crore, with a reduced net loss of ₹64.35 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.